NCT01568021已完成不适用
Post Market Surveillance of OZURDEX® for Branch Retinal Vein Occlusion (BRVO) and Central Retinal Vein Occlusion (CRVO)
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- Allergan
- 入组人数
- 100
- 主要终点
- Time to First Re-treatment
研究概览
简要总结
This multicenter observational study will assess the efficacy and tolerability of OZURDEX® in clinical practice, and will assess the time at which patients are considered for retreatment.
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Prospective
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Macular Edema
- •Prescribed OZURDEX®
排除标准
- 未提供
结局指标
主要结局
Time to First Re-treatment
时间窗: 1 Year
Time to first re-treatment was defined as the time in days between the first administration of Ozurdex® and the following administration of Ozurdex® (re-treatment) in the study eye.
次要结局
- Change From Baseline in Best Corrected Visual Acuity (BCVA) Score(Baseline, Weeks 12, 24 and 48)
- Change From Baseline in Central Retinal Thickness as Measured by Optical Coherence Tomography (OCT)(Baseline, Weeks 12, 24 and 48)
研究者
相似试验
进行中（未招募）
不适用
A Post-Market Study for Long-Term Effectiveness and Safety of the TOMAC System for RLSRestless Legs SyndromeNCT06076499Noctrix Health, Inc.325
已完成
不适用
Post Market Surveillance Study Evaluating BioFoam Surgical Matrix in Cardiovascular SurgeryCardiovascular ProceduresAortic Valve ReplacementType A Aortic DissectionThoracic Aortic AneurysmNCT02164201CryoLife Europa75
已完成
不适用
LifeVest Safety and Efficacy in Real Life Settings in FranceLeft Ventricular DysfunctionCardiac EventCardiac ArrythmiasSudden Cardiac DeathNCT03319160Zoll Medical Corporation1,164
已完成
不适用
Observational, Post Market Study in Treating Chronic Upper Extremity Limb PainUpper LimbPainNCT04466111SGX Procura LLC58
已完成
不适用
Multi Centre Study on TESS V2 Shoulder SystemOsteoarthritis ShoulderRevisionRheumatoid ArthritisAvascular NecrosisFractureRotator Cuff TearNCT03431857Zimmer Biomet106